A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec Docetaxel in Patients With Solid Tumours

Trial Profile

A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec Docetaxel in Patients With Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms NAPOLY
  • Sponsors Cristal Therapeutics
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 18 Jul 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 29 Apr 2016 According to Cristal Therapeutics media release, company has initiated this trial in July 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top